Retrospective Multicenter Study Comparing Chemotherapy and CDK4/6 Inhibitors in Luminal Subtype Metastatic Breast Cancer Patients with Visceral Crisis
Breast Care · 14.11.2026
DOI: 10.1159/brc/abrag019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Care, online erschienen am 14.11.2026. Verfasst von Nahla Shaaban und 4 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Visceral crisis in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) has traditionally been regarded as an indication for cytotoxic chemotherapy. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) may offer comparable efficacy, but direct comparative real-world data remain scarce.
Methods
This retrospective study included 249 patients with luminal subtype MBC and visceral crisis at six centers in Egypt and Saudi Arabia, treated with CDK4/6i plus ET (n = 123) or chemotherapy (n = 126). Co-primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints were objective response rate (ORR), clinical benefit rate (CBR), toxicity, and pre-specified hormone receptor subgroup analyses. Multivariable Cox regression adjusted for potential confounders.
Results
ECOG performance status was significantly better in the CDK4/6i+ET group (ECOG 0: 21.1% vs. 9.5%; ECOG 1: 58.5% vs. 74.6%; p = 0.021), whereas liver metastases (58.5% vs. 54.0%; p = 0.468) and clinically relevant hepatic impairment (26.8% vs. 30.2%; p = 0.561) were comparable. ORR was 60.2% (95% CI 51.3–68.4) versus 52.4% (43.7–60.9) (p = 0.267), and CBR 82.9% versus 74.6% (p = 0.147). Median PFS was 8.5 versus 7.4 months and median OS 20.5 versus 14.8 months. CDK4/6i+ET was associated with longer PFS (HR 0.57; 95% CI 0.40–0.80; p = 0.0011) and OS (HR 0.57; 95% CI 0.38–0.86; p = 0.0076), associations that persisted after multivariable adjustment (PFS adjusted HR 0.55, p < 0.001; OS adjusted HR 0.55, p = 0.008). HER2 score +2 was the only other independent predictor. PFS benefit was consistent across receptor strata. In exploratory analyses, the OS association was strongest in ER-low (<50%) tumours (HR 0.32; 95% CI 0.11–0.89) versus ER-high (HR 0.73; 95% CI 0.46–1.16), with a non-significant interaction (p = 0.081) and small subgroups. Grade 3–4 neutropenia was more frequent with CDK4/6i+ET (65.9% vs. 7.9%) and grade 3–4 non-haematological toxicity with chemotherapy.
Conclusions
In this non-randomised cohort, CDK4/6i plus ET was associated with longer PFS and OS than chemotherapy in luminal MBC with visceral crisis. Because allocation was non-random and baseline performance status favoured the CDK4/6i+ET group, these associations cannot be interpreted as causal and do not establish superiority. The findings are hypothesis-generating and support prospective randomised trials rather than a change to current guideline recommendations. Keywords: metastatic breast cancer; visceral crisis; CDK4/6 inhibitors; endocrine therapy; chemotherapy; progression-free survival; overall survival
Zitieren
APA
Shaaban, N., Korani, O. M., Mostafa, A., Moawad, H., & Sohaib, A. (2026). Retrospective Multicenter Study Comparing Chemotherapy and CDK4/6 Inhibitors in Luminal Subtype Metastatic Breast Cancer Patients with Visceral Crisis. Breast Care. https://doi.org/10.1159/brc/abrag019
Vancouver
Shaaban N, Korani OM, Mostafa A, Moawad H, Sohaib A. Retrospective Multicenter Study Comparing Chemotherapy and CDK4/6 Inhibitors in Luminal Subtype Metastatic Breast Cancer Patients with Visceral Crisis. Breast Care. 2026. doi:10.1159/brc/abrag019
BibTeX
@article{Shaaban2026,
author = {Shaaban, Nahla and Korani, Omnia Mohamed and Mostafa, Ahmed and Moawad, Hany and Sohaib, Ahmed},
title = {Retrospective Multicenter Study Comparing Chemotherapy and CDK4/6 Inhibitors in Luminal Subtype Metastatic Breast Cancer Patients with Visceral Crisis},
journal = {Breast Care},
year = {2026},
doi = {10.1159/brc/abrag019}
}
EUVIMED